Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Regional Observatory on Metabolic Syndrome- LAZIO (ORSA)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: May 29, 2008
Last updated: December 2, 2010
Last verified: December 2010
The aim of the study, is to assess the prevalence of Metabolic Syndrome in Italy on a regional basis, defined according to NCEP/ATPIII Guidelines criteria.

Metabolic Syndrome

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: Regional Observatory on Metabolic Syndrome in Italy- LAZIO

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Prevalence of Metabolic Syndrome in Primary Care Population. [ Time Frame: At Visit ]

Secondary Outcome Measures:
  • Concomitant presence of other CV risk factors. [ Time Frame: At Visit ]

Enrollment: 1574
Study Start Date: October 2007
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Primary care population


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic

Inclusion Criteria:

  • lipid profile in the last year
  • Signed informed consent

Exclusion Criteria:

  • Subjects with serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's successful participation in the study
  • Pregnancy or breast feeding
  • Subject who are unwilling or unable to provide the informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00689455

Research Site
Rieti, Italy
Research Site
ROme, Italy
Research Site
Viterbo, Italy
Sponsors and Collaborators
Study Chair: Volpe Massimo, MD, FACC Cardiology Dept. Director, Sapienza University, Sant' Andrea Hospital, Rome
  More Information

Responsible Party: Mario Mangrella MD Medical Manager, Cardiometabolic Team, AstraZeneca S.p.A. Identifier: NCT00689455     History of Changes
Other Study ID Numbers: NIS-CIT-DUM-2008/2 
Study First Received: May 29, 2008
Last Updated: December 2, 2010
Health Authority: Italy: Ethics Committee

Keywords provided by AstraZeneca:
Metabolic Syndrome
Waist Circumference

Additional relevant MeSH terms:
Metabolic Syndrome X
Pathologic Processes
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases processed this record on October 21, 2016